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Abstract
Mortality in patients with human immunodeﬁciency virus (HIV)-associated tuberculosis (TB) is high, particularly in sub-Saharan Africa.
This study aimed to compare mortality and predictors of mortality in those who were antiretroviral therapy (ART) naïve to those with
prior ART exposure.
This retrospective cohort study was conducted in Serowe/Palapye District, Botswana, a predominantly urban district with a large
burden of HIV-associated TB with a high case fatality. Between January 1, 2013 and December 31, 2013, patients conﬁrmed with
HIV-associated TB were enrolled and followed up. Kaplan–Meier and Cox proportional hazard modeling was undertaken to identify
predictors of mortality, with ART initiation included as time-updated variable.
Among the 300 patients enrolled in the study, 131 had started ART before TB diagnosis (44%). There were 45 deaths. There was
no difference in mortality between ART-naïve patients and those with prior ART exposure. In the multivariate analysis, no ART use
during TB treatment (hazard ratio [HR]=5.6, 95% conﬁdence interval [CI]=2.9–11; P< .001), opportunistic infections other than TB
(HR=8.5, 95% CI=4–18.4; P= .013), age ≥60 years (HR=4.8, 95% CI=1.8–13; P= .002), hemoglobin <10g/dL (HR=2.4, 95%
CI=1.3–4.5) and hepatotoxicity (HR=5, 95% CI=1.6–17; P= .007) were associated with increased mortality. In the subgroup
analysis, among ART-naïve patients, no ART use during TB treatment (HR=8.1, 95% CI=3.4–19.4; P< .001), opportunistic
infections other than TB (HR=16, 95% CI=6.2–42; P< .001), and hepatotoxicity (HR=8.3, 95% CI=2.6–27; P< .001) were
associated with mortality. Among patients with prior ART exposure, opportunistic infections other than TB (HR=6, 95%CI=2.6–27;
P< .001) were associated with mortality.
Mortality in patients with HIV-associated TB is still high. To reduce mortality, close clinical monitoring of patients together with
initiation of ART during TB treatment is indicated.
Abbreviations: 3TC = lamivudine, ART = antiretroviral therapy, AZT = zidovudine, EFV = efavirenz, FTC = emtricitabine, HIV =
human immunodeﬁciency virus, LPV/r = ritonavir-boosted lopinavir, NVP = nevirapine, TB = tuberculosis, TDF = tenofovir.
Keywords: deaths, human immunodeﬁciency virus, mycobacterium infection, outcomes, risk factors, tuberculosis
1. Introduction 2016, there were an estimated 10.4 million cases of TB, 10%
of whom were coinfected with HIV, resulting in 400,000 deaths.Mortality in patients with human immunodeﬁciency virus
(HIV)-associated tuberculosis (TB) is high.[1–3] Globally inEditor: Akhilanand Chaurasia.
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1Sub-Saharan Africa accounts for 80% of these deaths.[1]
In Botswana, a country with a high HIV burden, TB was
declared a public health emergency in 2005. By 2016, the
incidence of TB was 326 per 100,000, the seventh highest in the
world, and 60% of these TB cases were TB-HIV coinfected. In
2016, a mortality rate of 62 per 100,000 was reported among
TB-HIV coinfected patients.[1] With universal access to
antiretroviral therapy (ART), there has been a sustained
decline in the number of TB cases. However, mortality in
people with HIV-associated TB is almost double that of people
not HIV infected.[1]
Several Southern African studies have reported on the
predictors of mortality in TB-HIV coinfected patients.[4–6]
However, in Botswana, the predictors of mortality in TB-HIV
coinfected patients have not been documented. If we knew what
the predictors of mortality in TB-HIV coinfected patients in
Botswana were, this knowledge could be used to inform
appropriate policy and patient care.
In this study on TB treatment among TB-HIV coinfected
patients in Botswana, we compared the mortality and predictors
of mortality in patients who were not on ART at the time that TB
treatment was initiated (ART-naïve patients) with the mortality
and predictors of mortality in patients who were on ART at the
time of TB treatment initiation (prior ART exposure).
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2.1. Study design
This was a retrospective cohort study assessing the predictors of
mortality in both ART-naïve patients and those with prior ART
exposure during HIV-associated TB treatment.2.2. Study setting
This retrospective cohort study was conducted in Serowe/Palapye
District, Botswana, a predominantly urban district with a large
burden of HIV-associated TB with a high case fatality. In
accordance with country guidelines,[7] all TB patients are
screened for HIV using the double rapid HIV test. The ﬁrst-
line TB treatment during the study period was rifampicin,
pyrazinamide, ethambutol, and isoniazid during the 2 initial
months (“intensive phase”), followed by rifampicin, isoniazid,
and ethambutol for the next 4 months (“continuation phase”).
However, in patients with central nervous system diseases or TB
infection in their bones, the continuation phase was extended to
12 months.[7] All patients with HIV-associated TB were eligible
for ART initiation during TB treatment.
Furthermore, the standard ART ﬁrst-line regimen for TB
patients was: tenofovir (TDF) + emtricitabine (FTC) or
Lamivudine (3TC) + efavirenz (EFV). Nevirapine (NVP) was
used in cases of EFV intolerance. The standard ART second-line
regimen was zidovudine (AZT) + lamivudine (3TC) and double
dosed LPV/r (ritonavir-boosted lopinavir).
While ART treatment was provided free of charge to all HIV-
positive citizens of Botswana, TB treatment was free of charge
regardless of citizenship. Generally, TB diagnosis (smear
microscopy) was done in primary and district hospital laborato-
ries while culture and drug sensitivity testing was done at the
National Health Laboratory in Gaborone. HIV-positive patients
were treated in all clinics and hospitals in the district, where the
patients were seen on a daily basis as outpatients. Directly
observed treatment was uniformly performed at all centers.2.3. Study population
Between January 1, 2013 and December 31, 2013, 300
conﬁrmed[7] HIV-infected patients ≥15 years old with a
laboratory- or x-ray-conﬁrmed diagnosis of TB and medical
records available were enrolled and followed up.Medical records
and TB and ART registers were reviewed at the time of TB
diagnosis and 18 months later to evaluate the outcomes and to
obtain all the dependent and independent variables, including
information on socio-demographic factors, lifestyle factors,
clinical characteristics, and laboratory proﬁles. ART initiation
was included as time-updated variable.
Patients were categorized according to their ART status at the
time of their TB diagnosis. Patients were deﬁned as ART naïve if
they were not on ART at the time of their TB diagnosis or had
been on ART for <3 months prior to their TB diagnosis. Patients
deﬁned as having previous exposure to ART had been on ART
for ≥3 months at the time of their TB diagnosis.2.4. Outcomes
The primary outcome was mortality, deﬁned as any death that
occurred during TB treatment, which varied from 6 months in
new TB cases, 8 months in repeat TB cases, 12 months in TB
meningitis cases, and up to 18 months in bone TB cases. Major2side effects were deﬁned as any side effect that occurred during TB
treatment requiring ﬁrst-line TB treatment to be discontinued.[8]2.5. Data collection and statistical analysis
We reviewed medical records to collect baseline demographic,
clinical, pharmaceutical, and laboratory data. Patient response to
treatment was then collected from medical records, the
laboratory database and TB and ART registers. Based on the
assumptions of a previous study,[9] with 80% power and a
signiﬁcance level of .05, an estimated sample size of 300 was
enrolled in the study.
The distribution of baseline characteristics was compared
using the chi-square test and Fisher exact test for categorical
variables and theMann–WhitneyU test for continuous variables.
The Kaplan–Meier method was used to compare time to death
for the overall group, namely the ART-naïve group and the group
with prior ART exposure. The Logrank test was used to compare
survival time between ART-naïve patients and patients with prior
ART exposure. Patients who did not experience the event
measuredwere considered censored at the date of their last visit to
the clinic during the study period. To identify independent
predictors of mortality, Cox proportional hazard regression was
undertaken. All multivariate models used a univariate threshold
of P .1 for the variables to be considered for inclusion. Analyses
were conducted using SPSS 21, IBM Corp., Armonk, New York.
All results were presented in the form of hazard ratios (HR)
and 95% conﬁdence intervals (CI). The level of signiﬁcance was
set at .05.2.6. Ethics approval
Ethics approval to conduct the study was obtained from
Stellenbosch University (Ethics Ref No S15/05/116), theMinistry
of Health of Botswana (Ref No PPME13/18/1 PS V [357]) and
the local health authorities in Serowe/Palapye District. Data
routinely collected by health workers for clinical care were used
in this study. To protect patient conﬁdentiality and anonymity,
the databases were de-identiﬁed and access was strictly limited.
Informed consent was waived by the ethics committees as the
study used data previously collected for clinical routine care and
posed no additional risks to patients.3. Results
Between January 1, 2013 and December 31, 2013, 551 TB
patients were initiated on TB treatment in Serowe/Palapye
District, of whom 388 (70%)were coinfected with HIV. Of these,
300 (77%) were enrolled in the study (Fig. 1).
Of the 300 patients enrolled in the study, 169 (56.3%) patients
were classiﬁed as ART naïve and 131 (44%) had previously
started ART. Of the 169 ART-naïve patients, 126 (74.6%)
commenced ART during TB treatment (Table 1). At baseline,
there were a number of signiﬁcant differences between patients
previously started on ART and those who were ART naïve. ART-
naïve patients were younger (median 42.6 vs 38.8; P= .004),
more frequently developed immune reconstitution inﬂammatory
syndrome (25.4% vs 9.2%; P< .001), more frequently had
unexplained anemia (Hb<10g/dL) (59% vs 27%; P< .001) and
had lower CD4 cell counts at TB diagnosis (47.3% vs 23.7%;
P< .001). In contrast, patients with prior ART initiation were
more likely to have had a previous episode of TB (19.1% vs
5.3%; P< .001). In ART-naïve patients, two-thirds (109/169;
551 Paents were assessed for eligibility
163 were HIV-negave    
therefore excluded 
               388 were screened 
88 had medical records 
missing or not captured 
hence excluded 
               300 were enrolled
169 were included in the group of 
ART-naïve paents  
131 were included in the group 
of with prior ART exposure  
Figure 1. Flow chart of the enrolment of the study population, Serowe/Palapye
district, Botswana, 2013. ART=antiretroviral therapy.
Table 1
Baseline demographic and clinical characteristics of TB patients








Age (mean [SD]) 38.8 (11.3) 42.6 (11.2) .004
Male sex 99 (58.6) 71 (54.2) .260
Unemployed
∗
114 (67.5) 93 (71) .499
Single† 144 (85.2) 112 (85.5) .997
Smoker‡ 2 (1.2) 4 (3.1) .401
Body weightx (mean [SD]) 51.3 (10.5) 50.6 (10.2) .665
Smear positive PTB 85 (50.3) 62 (47.3) .579
Extrapulmonary 42 (24.8) 39 (29.8) .395
Previous TB 9 (5.3) 25 (19.1) <.001
Feverjj 78 (46.2) 49 (37.4) .168
Productive coughjj 119 (70.4) 93 (71) .860
Night sweatsjj 56 (33.1) 36 (27.5) .477
Loss of weightjj 111 (65.7) 69 (52.7) .060
Duration of symptoms >3 months¶ 21 (12.4) 23 (17.6) .239
ART use during TB treatment 126 (74.6) 131 (100) <.001
OI other than TB 11 (6.5) 8 (6.1) .959
Total white blood cells# 103/mL 6.01 (2–33) 7.43 (3–56) .54
CD4
∗∗
counts cells/mL at TB <200 80 (47.3) 31 (23.7) <.001
CD4†† counts cells/mL at ART initiation
<200 68 (40.2) 64 (48.9)
200–350 23 (13.6) 18 (13.7)
351–500 8 (4.7) 5 (3.8)
>500 10 (5.9) 1 (0.8) .142
Hemoglobin‡‡ <10g/dL 59 (34.9) 26 (19.8) <.001
Major side effect 7 (4.1) 2 (1.5) .398
IRIS 43 (25.4) 12 (9.2) .001
ART= antiretroviral therapy, IRIS= immune reconstitution inﬂammatory syndrome, SD= standard
deviation, TB= tuberculosis.
Major side effect found were Hepatoxicity (8/9), and Stevens Johnson syndrome 1/9 OI: opportunistic
infection. Time-updated variables: CD4 counts cells/mL at ART initiation and ART use during TB
treatment.
∗
Missing data for 22 patients (7.3%).
†Missing data for 21 patients (7%).
‡Missing data for 125 patients (41.7%).
xMissing data for 87 patients (29%).
jjMissing data for 21 to 25 patients (7–8.3%).
¶ Missing data for 68 patients (22.7%).
# Missing data for 98 patients (32.7%). Median (minimum–maximum).
∗∗
Missing data for 57 (19%).
††Missing data for 60 (20%).
‡‡Missing data for 84 patients (28%).
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and 40% had a CD4 cell count <200cells/mL. Of the CD4 cell
counts recorded among patients previously on ART, in all but
one of the patients (87/88) the CD4 cell count at ART initiation
was >500cells/mL (Table 1).
Besides TB, the other opportunistic infections reported were
HIV wasting syndrome (11–3.7%), cryptococcal meningitis (2–
0.67%), herpes simplex infection (1–0.33%), Kaposi sarcoma
(2–0.67%), Pneumocystis jirovecii pneumonia (2–0.67%), and
oral candidiasis (1–0.33%). Among patients documented to have
experienced amajor side effect, hepatotoxicity was reported in all
but 1 patient who had Stevens Johnson syndrome.
There were 45 deaths during the study period, with 27 deaths
(16%) amongst those who were ART naïve and 18 deaths
(13.7%) amongst those previously started onART. Eight patients
(2.67%) defaulted on treatment, and 5 patients (1.67%) were
transferred out to other facilities.
In Univariate Cox analyses (Table 2), there was no signiﬁcant
difference in mortality between ART-naïve patients and those
with prior ART initiation (P= .569). Predictors of mortality were
age ≥60 years (P= .012), loss of weight (P= .032), opportunistic
infections other than TB (P< .001), no ART use during TB
treatment (P= .005), CD4 cell counts <200cells/mL (P= .046),
hemoglobin<10g/dL (P= .007), and major side effect (P= .001).
In contrast, smear-positive TB (P= .028) was associated with a
signiﬁcantly lower risk of mortality.
In the overallmultivariate analysis (Table 2), noARTuse during
TB treatment (P< .001), opportunistic infections other than TB
(P= .013), age ≥60 years (P= .002), hemoglobin <10g/dL
(P= .029), and major side effect (P= .007) were signiﬁcantly
associated with higher mortality. The survival mean of the overall
group from time of TB diagnosis was 14.99 months (95% CI:
13.57–16.41). Themean survival time for patients on ART during
TB treatment was 15.43 months (95% CI: 13.8–17.01) while for
those not on ART, the mean survival time was 9.46 months (95%
CI: 7.62–11.3) with survival probability at 12 months of 0.625.
Among ART-naïve patients, 24 patients started ART within 4
weeks from the start of TB treatment and 16 patients >4 weeks
from the start of TB treatment. However, there were no3signiﬁcant difference in survival time between the 2 groups of
patients (log rank P= .832). The median time from ART
initiation to TB diagnosis in patients previously started on
ART was 37.15 months (interquartile range [IQR]: 13.93–
75.97), and themedian time inweeks fromHIV diagnosis to ART
initiation was 28.5 weeks (IQR: 4–150).
Multivariate survival analyses per subgroup were performed.
The ﬁnal models are shown in Table 3. Among ART-naïve
patients, no ART use during TB treatment (P< .001), opportu-
nistic infections other than TB (P< .001) and major side effect
(P< .001) were signiﬁcantly associated with higher mortality.
Among patients previously started on ART, opportunistic
infections other than TB (P< .001) were signiﬁcantly associated
with higher mortality (Table 3).
There was no signiﬁcant difference in survival time between the
2 groups (log rank P= .568). The survival curve illustrates that
most patients died in the ﬁrst 3 months, there were few deaths
after 3 months and there was no death after 6 months (Fig. 2).
[4,9,10]
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<35 15 (33.3) 89 (34.9) 14.4 1 – – –
35–59 23 (51.1) 156 (61.2) 12.8 0.89 (0.46–1.7) .722 1.5 (0.75–3) .245
≥60 7 (15.6) 10 (3.9) 41.2 3.15 (1.28–7.73) .012 4.8 (1.8–13) .002
Male sex 28 (62.2) 142 (55.7) 16.5 1.22 (0.67–2.23) .513 – –
Unemployed 34 (75.6) 173 (67.8) 16.4 1.2 (0.59–2.42) .627 – –
Smoker 3 (6.7) 3 (1.2) 50 2.53 (0.76–8.42) .130 0.66 (0.13–3.4) .619
Body weight <50kg 17 (37.8) 85 (33.3) 16.7 2.1 (0.94–4.71) .072 1.8 (0.7–4.5) .205
Smear positive PTB 15 (33.3) 132 (51.8) 10.2 0.5 (0.27–0.93) .028 – –
Extrapulmonary 13 (28.9) 67 (26.3) 16.3 1.12 (0.59–2.13) .739 – –
Previous TB 4 (8.9) 30 (11.8) 11.8 0.74 (0.27–2.01) .571 – –
Fever 23 (51.1) 104 (40.8) 18.1 1.58 (0.85–2.94) .153 – –
Productive cough 31 (68.9) 181 (71) 14.6 0.94 (0.46–1.92) .870 – –
Night sweats 9 (20) 83 (32.5) 9.8 0.55 (0.26–1.16) .116 – –
Loss of weight 33 (73.3) 147 (57.6) 18.3 2.33 (1.07–5.04) .032 – –
Duration of symptoms >3 mo 7 (15.6) 37 (14.5) 15.9 3.85 (0.47–31) .207 – –
No ART use during TB treatment 15 (33.3) 28 (11) 34.9 2.49 (1.31–4.73) .005 5.6 (2.9–11) <.001
OI other than TB 12 (26.7) 7 (2.7) 63.2 7.76 (3.96–15.25) <.001 8.5 (4–18.4) <.001
Total white blood cells 103/mL – – – 1.03 (0.99–1.1) .135 – –
CD4 counts cells/mL at TB <200 21 (46.7) 90 (35.3) 18.9 2.02 (1.01–4.04) .046 – –
Hemoglobin <10g/dL 22 (48.9) 63 (24.7) 25.9 2.4 (1.3–4.5) .007 2.44 (1.3–4.6) .029
Major side effect 5 (11.1) 4 (1.6) 55.5 4.84 (2–12.3) .001 5 (1.6–17) .007
IRIS 9 (20) 46 (18) 16.4 1.1 (0.53–2.27) .808 – –
ART naïve 27 (60) 142 (55.7) 16 1.2 (0.66–2.2) .569 – –
Diabetes mellitus 0 5 (2) – 0.049 (0–2559) .586 – –
ART=antiretroviral therapy, CI= conﬁdence interval, major side effect found were Hepatoxicity (8/9), and Stevens Johnson syndrome 1/9, HR=hazard ratio, IRIS= immune reconstitution inﬂammatory
syndrome, OI= opportunistic infection. ART use during TB treatment: time-updated variable, TB= tuberculosis.
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Our study shows that mortality in TB-HIV coinfected patients
during TB treatment in Botswana is similar in ART-naïve patients
and those with prior ART exposure. In addition, we report that
the predictors of mortality vary according to ART status at TB
diagnosis.
In this cohort of TB-HIV coinfected patients, 44% patients
were previously started on ART, a proportion that is similar toTable 3
Predictors of death in TB patients in subgroups deﬁned according






Major side effect 7.7 0.99–60 .128




<50 2.8 0.82–9.4 .101
ART use during TB
Yes 1
No 8.1 3.4–19.4 <.001
OI other than TB 16 6.2–42 <.001
Major side effect 8.3 2.6–27 <.001
ART=antiretroviral therapy, CI=conﬁdence interval, HR=hazard ratio, OI= opportunistic infection,
TB= tuberculosis.
∗
Adjusted for weight at TB, ART use during TB, weight loss, smear positive, major side effect, CD4
group at TB diagnosis, opportunistic infection, age group, and hemoglobin group. Major side effect
found were hepatoxicity (8/9), and Stevens Johnson syndrome 1/9. ART use during TB treatment:
time-updated variable.
4that reported in other studies. Our ﬁnding supports the
evidence that the incidence of TB among HIV patients on long-
term ART is still higher as compared with the general
population.[5,6,11] Hence, it is predictable that in areas where
access to ART has beenwidely available for a long period, such as
Botswana, a signiﬁcant proportion of patients presenting with TB
will not be naïve to ART.[9]Figure 2. Kaplan–Meier survival estimates according to study subgroup. The 2
subgroups of patients were categorized based on their ART status at the time
of their TB diagnosis: ART naïve: not on ART or had been on ART for <3
months prior to their TB diagnosis, previously on ART: had been on ART for ≥3
months at the time of their TB diagnosis. ART=antiretroviral therapy, TB=
tuberculosis.
[6]
Muyaya et al. Medicine (2018) 97:16 www.md-journal.comLawn et al have documented that the long-term risk of TB
incidence in HIV-infected patients is strongly associated with
CD4 cell counts <500cells/mL; we also found that most of
patients on ART presenting with TB disease had CD4 cell counts
<500cells/mL at the time of ART initiation. These ﬁndings
suggest that the impact of ART on the TB disease burden will be
greatly improved by ART policies that minimize the time that
patients spend with CD4 cell counts <500cells/mL.[6,12–14]
Among ART-naïve patients, only 75% were commenced on
ART during TB treatment, a proportion similar to that reported
by others studies[9,15] and the Botswana National TB pro-
gramme.[1] This ﬁnding is probably related to poor guideline
implementation and integration of TB and HIV care.[3,16,17]
The analysis of predictors of mortality in the overall study
population showed that mortality was higher among patients
who were not initiated on ART during TB treatment, had
opportunistic infections other than TB, experienced a major side
effect during TB treatment, were older and had anemia. Some of
these ﬁndings are consistent with those of other stud-
ies.[4,5,9,10,18,19]
Furthermore, patients not on ART during TB treatment had a
5.6-fold increased risk of mortality (95% CI: 2.9–11) compared
with patients on ART. Although the beneﬁcial role of ART in the
management of patients with TB-HIV coinfection is well
documented,[18–22] the time of ART initiation during TB
treatment is still controversial, especially regarding the threshold
of CD4 cell counts. Recent trials have demonstrated a beneﬁcial
impact of ART initiation 2 to 4 weeks after the initiation of TB
treatment in patients with advanced immunodeﬁciency.[23,24]
Although a recent review reports improved survival if ART is
initiated early in TB-HIV coinfected patients with advanced
immunodeﬁciency, there are also reports that there is insufﬁcient
evidence to support a survival beneﬁt conferred by early ART
initiation in patients with CD4 cell counts >50cells/mL.[25]
Furthermore, TB-HIV coinfected patients with opportunistic
infection was associated with an 8.5-fold increased risk of
mortality (95% CI: 4–18.4) compared with those with only TB-
HIV coinfection. This ﬁnding was consistent with those of other
studies.[15,19,20,26–28]
The occurrence of major side effects during TB treatment was
found to be strongly associated with an increased risk of
mortality (HR: 5, 95%CI: 1.6–17). Among patients documented
to have experienced a major side effect, hepatotoxicity was
reported in all but 1 patient who had Stevens Johnson syndrome.
Previous studies have documented the association between
hepatotoxicity and mortality.[29,30] This evidence highlights the
importance of close monitoring of patients during TB treatment,
especially during the ﬁrst 2 months of TB treatment and at the
time of ART initiation.
Our study has added to the literature that reports the strong
association between mortality and unexplained anemia (Hb<10
g/dL, HR: 2.4, 95% CI: 1.3–4.5). This ﬁnding suggests that in
TB-HIV coinfected patients, at the time of TB diagnosis baseline
blood tests, including a full blood count should be done to
exclude anemia. Other studies have also reported anemia as an
HIV-related complication in HIV-infected persons.[31]
In patients previously initiated on ART, opportunistic
infections other than TB were strongly associated with an
increase in mortality (HR: 6, 95% CI: 2–18). This could be
because of the poor adherence to ART observed in some of the
patients on ART presenting with active TB disease in this study.
Thus, continuous interventions are needed to improve adherence
to ART to reduce the likelihood of the occurrence of5opportunistic infections and to improve survival in this
population.[32]
In the ART-naïve group, thus no ART use during TB
treatment, the concurrence of opportunistic infection and the
occurrence of a major side effect were strongly associated with
increased risk of mortality (HR: 8.1, 16, and 8.3 and 95% CI:
3.4–19.4, 6.2–42, and 2.6–27, respectively). Possible reasons
might be poor implementation of clinical guidelines, the
challenges of the integration of TB-HIV care, inadequate clinical
monitoring, and late presentation, which may limit the beneﬁt
that early ART can provide to this subgroup of patients in whom
the diagnosis of HIV was mostly made at the time of TB
diagnosis.[9]
The limitations of the study included the fact that it was a
retrospective observational study using data from routine
medical records in the public health sector. At the time, some
data were missing or incomplete. For example, white blood cell
differentials were not included in the multivariate analyses as so
much data were missing. Further research could explore the role
of white blood cell differentials, especially the neutrophil count.
Furthermore, due to the relatively low mortality by study
group of interest, there could be a possibility of a Type 2 error
to detect a statistically signiﬁcant difference in the proportion
of patients who died in the 2 groups of interest (ART naïve vs
prior ART). In addition, as the sample size of this study was
estimated based on a study conducted in Brazil, further
research could be undertaken using a sample size estimated
based of Southern Africa data with similar TB-HIV epidemiol-
ogy to Botswana.
Although this study was conducted in 1 district in Botswana
only, as this district is similar to other districts with regard to TB
and HIV characteristics, the results can be generalized to the
country as a whole.5. Conclusion
We conclude that our study in Botswana, a setting with limited
resources, demonstrates that even after a long period of universal
access to ART, the rate of mortality in HIV-TB coinfected
patients is still high. Our ﬁndings suggest that to reduce mortality
in patients on treatment for HIV-associated TB, more careful
clinical monitoring of patients together with initiation of ART
during TB treatment is indicated.Acknowledgments
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